SeqGeq v1.6 is the latest in bioinformatics platforms available from the team at BD Life Sciences. This update contains new features which support the analysis of bulk sequencing datasets.
Sep 25, 2019 | scRNA-Seq
Vaccines provide immunity by stimulating a set of naive B cells to become antibody-producing plasma cells against a specific pathogen. However, plasma cells have varying lifespans, which is why some vaccines, such as measles and HPV, require boosters, because once all the pathogen-specific plasma cells die, immunity ends. What drives this variation? How can we prolong a plasma cell’s life? Can longer-living plasma cells help create enduring vaccines? Could shortening a plasma cell’s lifespan prevent damage to an autoimmune patient? A team of researchers, led by Wing Lam of Washington University, sought to answer these questions about plasma cell longevity in their recent study.
Idiopathic pulmonary fibrosis (IPF), a chronic lung disease claiming approximately 30,000 to 40,000 victims every year, is characterized by rapid lung degeneration and a dismal median survival of 3-5 years after diagnosis. Despite a clear need for treatments that can improve this prognosis, there are currently only two therapies available for the treatment of IPF. While these two therapies have been shown to slow disease progression, neither treatment can actually halt lung degeneration or reverse lung tissue remodeling.